Mad Honey Cardiovascular Effects: Bradycardia, AV Block, and Hypotension Explained

Mad honey’s clinical effects are predominantly cardiovascular. This is not incidental; it follows directly from the distribution of voltage-gated sodium channels and from what those channels do in the tissue where they are most critical.

The heart coordinates its contractions through precisely timed electrical signals. The sinoatrial node generates the impulse, the atrioventricular node gates its passage to the ventricles, and the His-Purkinje network distributes it across the ventricular muscle to produce synchronized contraction. Every one of those steps depends on voltage-gated sodium channels functioning normally, activating within microseconds to initiate each action potential and inactivating just as rapidly to allow the system to reset for the next beat. When grayanotoxin prevents that inactivation, the cardiac electrical system is disrupted at multiple levels simultaneously.

The neurological symptoms of mad honey poisoning, dizziness, tingling, visual disturbances, and altered consciousness at high doses, are almost entirely secondary to what the cardiovascular disruption produces downstream. Reduced cardiac output drops blood pressure. The brain receives less oxygenated blood per unit time. The sensory symptoms follow from cerebral hypoperfusion and peripheral nerve disruption, not from any direct central nervous system receptor mechanism. Understanding the cardiovascular effects is therefore the mechanistic foundation for understanding almost everything else that happens in mad honey poisoning.

Three Simultaneous Cardiovascular Mechanisms

GTX does not produce cardiovascular effects through a single pathway. Three distinct mechanisms operate simultaneously from the moment of significant systemic absorption, and their combined effect is the clinical triad of bradycardia, hypotension, and AV conduction impairment.

Mechanism 1, Vagal overstimulation

Grayanotoxin activates voltage-gated sodium channels in the neurons of the autonomic nervous system that regulate cardiac function. In the parasympathetic (vagal) pathway, sustained Na+ channel activation amplifies acetylcholine release at the cardiac nerve terminal. Acetylcholine binds to M2 muscarinic receptors at the sinoatrial and atrioventricular nodes, activating the inward rectifier potassium current (IKACh), which hyperpolarises the nodal membrane and slows spontaneous depolarisation. The result is reduced SA node firing rate, bradycardia, and slowed AV conduction.

This vagal mechanism is confirmed by the clinical response to atropine. Atropine is a competitive M2 receptor antagonist. Its efficacy at reversing GTX-induced bradycardia in most cases proves that vagal overstimulation, mediated through muscarinic receptors, is the dominant pathway. The heart’s intrinsic pacemaker function is suppressed by excess acetylcholine signalling, but it is not damaged.

Mechanism 2, Direct cardiac tissue disruption

GTX does not act only through the autonomic nervous system. It also acts directly on voltage-gated sodium channels in the cardiac conduction tissue itself, the SA node, AV node, bundle of His, and Purkinje fibres. By preventing Na+ channel inactivation in these cells, GTX prolongs the action potential duration, delays the restoration of membrane excitability, and impairs the precisely timed electrical propagation on which coordinated cardiac conduction depends.

This direct component is clinically significant because it explains why some severe cases do not respond fully to atropine. Blocking M2 receptors addresses the vagal pathway; it does not reverse the direct VGSC effect on nodal and conduction tissue. Cases requiring catecholamine support or temporary pacemaker insertion likely involve substantial direct conduction tissue disruption beyond what muscarinic blockade can overcome.

Mechanism 3, Peripheral vasodilation

GTX disrupts sodium channel function in the sympathetic neurons that maintain vascular smooth muscle tone. Normal arterial blood pressure is maintained in part by tonic sympathetic vasoconstriction, continuous low-level noradrenaline release, keeping the arterioles partially contracted. GTX-induced sustained depolarisation in these sympathetic neurons eventually impairs their normal signaling capacity, reducing vasoconstrictor tone and allowing arteriolar relaxation. The result is peripheral vasodilation: systemic vascular resistance drops, and blood pressure falls independently of the heart rate effect.

The combination of reduced cardiac output from bradycardia and reduced vascular resistance from vasodilation is why hypotension in GTX poisoning is more pronounced and more resistant to spontaneous compensation than either mechanism alone would produce.

Bradycardia: The Primary Clinical Sign

Bradycardia, heart rate below 60 bpm, typically 40 to 50 bpm in moderate presentations and below 40 bpm in severe cases, is the most consistent cardiovascular finding across the entire clinical case record. In the Salici and Atayoglu (2015) systematic review of 1,199 Turkish cases, bradycardia was present in the overwhelming majority of presentations. It is the sign that most reliably triggers the differential diagnosis of mad honey poisoning in an emergency setting.

The SA node target

The sinoatrial node is an intrinsic pacemaker, a cluster of specialized cells in the right atrial wall that spontaneously depolarize at approximately 60 to 100 times per minute under resting conditions, setting the heart’s baseline rate. SA node automaticity depends on a carefully balanced interplay of ion channels, including the funny current (If), which drives spontaneous depolarisation during the diastolic interval. GTX disrupts this balance through the dual mechanism described above: vagal amplification hyperpolarises the nodal membrane and slows spontaneous depolarisation; direct VGSC disruption in nodal cells prolongs the action potential and delays reset. Both effects reduce firing rate.

Heart rates in documented cases range from 30 to 50 bpm in moderate presentations and below 30 bpm in severe ones. At 30 bpm, cardiac output, the product of heart rate and stroke volume, is reduced to approximately 40% of its normal resting value even if stroke volume is preserved, which is itself compromised by the concurrent hypotension, reducing ventricular filling.

The atropine reversal as a mechanistic confirmation

The consistent efficacy of atropine in reversing bradycardia across the case literature is both clinically important and pharmacologically informative. Atropine’s mechanism, competitive M2 receptor blockade, proves that the dominant pathway for bradycardia in most cases is vagally mediated, not the result of irreversible intrinsic pacemaker failure. The SA node resumes its normal rate when excess acetylcholine signaling is blocked, confirming that GTX-induced bradycardia is a functional suppression of normal automaticity, not structural damage.

Hypotension: The Blood Pressure Cascade

Hypotension in GTX poisoning is produced by two simultaneous and additive mechanisms: reduced cardiac output from bradycardia, and peripheral vasodilation from reduced sympathetic vasoconstrictor tone. Their combination creates a blood pressure drop that is greater than either would produce individually and that is more resistant to compensatory mechanisms.

Reduced cardiac output

At 40 bpm with a typical resting stroke volume, the heart delivers substantially less blood per minute than at the normal range of 60 to 80 bpm. The cardiovascular system’s primary compensatory mechanism for reduced heart rate is increased stroke volume via the Frank-Starling mechanism; the heart ejects more blood per beat as the ventricles fill more completely during the longer diastolic interval. This compensation is partially effective but limited, and it is further undermined by the concurrent vasodilation, reducing ventricular filling pressure.

Peripheral vasodilation

Reduced sympathetic vasoconstrictor tone allows arteriolar dilation and a fall in systemic vascular resistance. Blood pressure is the product of cardiac output and systemic vascular resistance. When both fall simultaneously, as they do in GTX poisoning, the blood pressure drop is proportionally more severe than the sum of the individual reductions.

Blood pressure in documented cases ranges from 70/40 mmHg in moderate presentations to unrecordable in severe cases. The Aryal (2025) Nepal case series documents one patient arriving with blood pressure not recordable, who recovered fully with saline, atropine, and adrenaline. Choi et al. (2017) estimated that GRAY-I blood concentrations of 2.52 to 4.55 ng/mL and GRAY-III concentrations of 17.5 to 27.3 ng/mL are associated with clinically significant hypotension, the closest available pharmacokinetic threshold data for the cardiovascular endpoint, derived from six patients.

AV Block: When the Conduction System Fails

The atrioventricular node is the electrical bridge between the atria and the ventricles. Normal cardiac function requires each atrial impulse to propagate through the AV node to the His-Purkinje network with appropriate timing, delayed just long enough to allow atrial contraction to top up ventricular filling before ventricular contraction begins, but not so delayed that the coordination is lost.

GTX disrupts AV conduction through the same dual mechanism that produces bradycardia: enhanced vagal tone slows conduction velocity through the richly vagally-innervated AV node, and direct VGSC disruption in AV nodal cells impairs action potential propagation. The two effects produce progressively more severe block as GTX exposure increases.

The block progression

First-degree AV block, a prolonged PR interval above 200 milliseconds, represents slowed but preserved conduction and is documented in moderate presentations. Second-degree block (Mobitz I or Wenckebach), progressive PR prolongation leading to a dropped beat as the AV node temporarily fails to conduct, indicates more significant conduction impairment. Third-degree or complete AV block, in which no atrial impulses pass to the ventricles and the two chambers beat independently, is the most severe conduction finding and carries the greatest hemodynamic risk, particularly when the ventricular escape rhythm is slow (20 to 40 bpm) and cannot maintain adequate cardiac output.

Reversibility, why the heart recovers

The reversibility of AV block with atropine in most cases is the clinical confirmation that vagal suppression of conduction is the dominant mechanism. In a complete AV block unresponsive to atropine, the additional direct VGSC disruption in nodal tissue has exceeded the capacity of muscarinic blockade to compensate. Temporary pacemaker insertion in these cases provides cardiac support while GTX clears, after which normal AV conduction resumes without permanent structural consequence. The literature documents no permanent AV conduction abnormality in patients who recovered from single-episode GTX poisoning.

Atrial Fibrillation and Other Arrhythmias

Sinus bradycardia and AV block are the most common cardiac findings in the clinical record, but they are not the only ones. Atrial fibrillation is documented in some mad honey cases, less commonly than the primary conduction findings, but with meaningful clinical significance. The mechanism involves sustained VGSC activation, creating conditions for re-entry circuits in atrial tissue: prolonged action potentials, heterogeneous repolarisation between adjacent cells, and the resulting electrical instability that allows chaotic depolarisation to replace the normally ordered atrial rhythm.

Ventricular escape rhythms appear in the context of complete AV block, activated by the ventricles’ intrinsic pacemaker when the AV bridge fails entirely. At the 20 to 40 bpm rates typical of ventricular escape, cardiac output is marginal, and hemodynamic instability is significant. ST-segment changes, repolarisation abnormalities rather than ischaemic changes, are documented in some cases. QT prolongation, reflecting extended action potential duration from sustained Na+ channel activation, is also documented. In clinical practice, distinguishing GTX-induced ST and QT changes from primary ischemia requires the history of honey consumption to anchor the diagnosis.

ECG Findings: A Reference Table

The electrocardiogram is the primary cardiovascular monitoring tool in mad honey poisoning. The findings range from mild conduction delay to complete heart block and are the primary basis for risk stratification and treatment decisions. ECG monitoring is recommended for all patients presenting with suspected GTX poisoning who have bradycardia, regardless of apparent initial symptom severity.

Dose-Dependence: What the Animal Data Shows

The dose-dependence of GTX cardiovascular effects is confirmed at the animal study level and provides the quantitative framework for understanding why batch concentration variability produces such variable clinical outcomes at equivalent gram-weight intake.

Turkmen et al. (2013) conducted a dose-escalation study in Sprague-Dawley rats using intraperitoneal GRAY-III injection at 0.2, 0.4, and 0.8 mg/kg body weight. Both mean arterial blood pressure and heart rate showed progressive, dose-dependent reductions across the three doses. The relationship was not linear; cardiovascular depression became disproportionately more pronounced at the highest dose, suggesting a threshold effect beyond which compensatory mechanisms are overwhelmed.

Translating animal data to human pharmacology

The Turkmen (2013) data cannot be directly transposed to human dose-response relationships. Species differences in Na+ channel distribution and density, pharmacokinetic differences between IP injection and oral honey consumption, and the difficulty of establishing concentration equivalence between experimental GRAY-III doses and honey GTX content all complicate direct comparison.

What the animal data establishes is the pharmacological reality of dose-dependence, a principle that is entirely consistent with the pattern seen across the clinical case literature. The same principle explains why moderately concentrated batches produce moderate bradycardia, and highly concentrated batches at the same gram weight produce complete AV block. It also explains why individual sensitivity factors, baseline heart rate, concurrent medications, and age shift the clinical presentation so substantially: a person with a resting heart rate of 55 bpm on a beta-blocker begins significantly closer to the symptomatic threshold for any given GTX exposure.

Why Atropine Works, and When It Does Not

The pharmacological basis for atropine’s efficacy in GTX poisoning illuminates the mechanism and the limits of treatment simultaneously.

Atropine is a competitive antagonist at muscarinic acetylcholine receptors. By occupying M2 receptors at the SA and AV nodes, it prevents the excess acetylcholine released by GTX-stimulated vagal neurons from slowing the heart and impairing conduction. This blockade is competitive; atropine and acetylcholine compete for the same receptor sites, and sufficient atropine overwhelms the vagal signal regardless of how much acetylcholine is being released. Atropine does not reverse the VGSC effect of GTX on cardiac tissue. It bypasses the vagal pathway that GTX exploits.

In the majority of documented cases, those where vagally-mediated bradycardia is the dominant mechanism, atropine is highly effective. Heart rate typically normalizes within minutes of IV administration, AV block resolves, and blood pressure recovers as cardiac output is restored. Ullah et al. (2018) document atropine responsiveness at doses ranging from 0.5 to 3 mg IV.

In cases where atropine is only partially effective or insufficient, the residual bradycardia and AV block represent the direct VGSC component, GTX-induced prolonged action potentials in SA and AV nodal tissue that are not mediated by muscarinic receptors and therefore cannot be addressed by muscarinic blockade. The clinical implication is that when atropine does not fully restore heart rate and conduction, the mechanism driving the residual abnormality is different, and the management escalates accordingly to catecholamine support or temporary pacing.

Risk Stratification: Who Is Most Vulnerable

Not all individuals face equal cardiovascular risk from GTX at comparable exposures. The clinical case record and pharmacological principles identify specific factors that substantially elevate the severity threshold for any given GTX load.

Pre-existing bradyarrhythmia is the highest-risk category. Sick sinus syndrome, pre-existing AV block, or any history of significant conduction abnormality means the cardiac electrical system is already compromised. GTX-induced additional slowing and conduction impairment can rapidly reach clinically dangerous levels from exposures that would be moderate in a healthy individual.

Beta-blockers represent the most important pharmacological interaction risk. Beta-1 receptor blockade reduces heart rate through a different pathway than GTX’s vagal effect; both reduce SA node firing, but through independent mechanisms. Their combination is additive or greater. A patient on a beta-blocker consuming mad honey from a moderately concentrated batch may develop complete AV block at a fraction of the intake that would produce only mild bradycardia in an untreated person.

Antihypertensives and calcium channel blockers reduce baseline blood pressure and vascular tone, narrowing the margin before GTX-induced vasodilation and reduced cardiac output produce hemodynamically significant hypotension. Age reduces cardiovascular reserve across multiple dimensions, SA node automaticity, AV conduction velocity, vascular responsiveness to sympathetic tone, and the ability to mount compensatory responses. Elderly individuals are documented as more severe presenters in the case record at equivalent estimated intake levels.

What We Don’t Know Yet

Several mechanistically important questions about GTX cardiovascular effects remain unresolved in the peer-reviewed literature.

No controlled human cardiac dose-response study exists. The Turkmen (2013) animal data provide the best available quantitative dose-response framework, but its translation to human pharmacokinetics is not validated. The relationship between honeygram weight consumed, resultant blood GTX concentration, and severity of cardiovascular effect in humans, across the full range of batch concentrations and individual sensitivity factors, has not been characterized in a controlled study. This is the gap that makes any specific dosing guidance for cardiovascular safety pharmacologically imprecise.

The individual variation in severity is not mechanistically explained. Why some individuals develop complete AV block from exposures that produce only mild sinus bradycardia in others is not fully characterized. Variation in cardiac Na+ channel subunit expression, vagal innervation density at the AV node, and individual pharmacokinetics are plausible contributors, but none have been quantified in a way that supports prospective severity prediction from clinical history alone.

The direct versus vagal contribution in severe cases has not been quantified. In presentations where atropine provides only partial reversal, the proportion of the residual effect attributable to direct nodal VGSC disruption versus incomplete vagal blockade has not been measured. Understanding this division more precisely would improve both mechanistic characterization and treatment selection.

Long-term cardiac effects from single-episode GTX exposure are assumed to be absent on the basis of rapid clinical resolution, but no systematic study with serial ECG or formal cardiac function assessment has been conducted across a meaningful patient cohort at any severity level.

Summary

Grayanotoxin produces cardiovascular effects through three simultaneous and pharmacologically distinct mechanisms: vagal overstimulation, slowing the SA node and AV conduction; direct VGSC disruption in cardiac conduction tissue, impairing action potential propagation; and peripheral vasodilation, reducing systemic vascular resistance. All three operate from the same molecular event, sodium channel inactivation failure, but through different anatomical pathways.

The clinical result is the consistent triad: bradycardia (typically 40 to 50 bpm in moderate cases, below 40 in severe), hypotension from combined reduced cardiac output and vasodilation, and AV conduction impairment ranging from first-degree block to complete AV block requiring temporary pacing. Atropine reverses the vagally mediated components in most cases. Where it does not, direct conduction tissue disruption is the likely residual mechanism.

The cardiovascular effects are dose-dependent and concentration-variable. A batch certifying GTX I at 0.75 µg/g and one at 64.86 µg/g deliver 86-fold different active compound exposure from the same gram weight, and produce 86-fold different cardiovascular challenge. Individual risk stratification, cardiac history, medications, age, and baseline heart rate determine how much margin exists before any given exposure becomes clinically serious.

Bradycardia below 50 bpm, inability to stand, or syncope after consuming mad honey are emergency symptoms requiring immediate medical attention.